Oct 6, 2021 | Cancer Center News
Photo of Sara Pedron Haba. Urbana, Ill. – Many Cancer Center at Illinois (CCIL) researchers have been focusing on glioblastomas, a type of brain cancer that is very aggressive, invasive, and incurable. Sara Pedron Haba, a research assistant professor in chemical and...
Feb 8, 2021 | Cancer Center News
In 2019, Hua Li, research associate professor of bioengineering, was awarded more than $2M from the National Cancer Institute (NCI) shortly after joining the University of Illinois. Since receiving the NCI funds, Li, also a clinical medical physicist at Carle...
Nov 19, 2020 | Cancer Center News
ILLINOIS — A desire to improve the status of cancer patient treatments led former theoretical physicist, Jun Song (PhD), to pivot his career towards cancer research. He spent several years learning about cancer biology and retraining to apply his background in...
Jul 16, 2020 | Cancer Center News
Brendan Harley, CCIL Research Program Leader and Professor of Chemical and Biomolecular Engineering, is studying glioblastoma, an aggressive form of brain cancer. In collaboration with other researchers, Harley’s lab is developing platforms to help scientists...
Apr 21, 2020 | Cancer Center News
Timothy M. Fan, Professor of Veterinary Oncology, has been appointed as program leader of the Cancer Center at Illinois (CCIL) research program in Cancer Discovery Platforms Across the Engineering-Biology Continuum. Fan will co-lead this research program with Brendan...
Mar 12, 2020 | Cancer Center News
Brendan Harley, Professor of Chemical and Biomolecular Engineering and CCIL Program Leader, is studying neurodegenerative disease models with the Director’s Innovation Fund and further support from the NCI. The DIF was initiated by alumnus Scott Fisher to honor...
Aug 2, 2019 | Cancer Center News, Student Spotlight
Bingtao Tang, PhD Candidate, Molecular and Integrative Physiology C*STAR Program, 2018 Cohort What led to your interest in cancer research? I received my bachelor’s degree in bioengineering from Xi’an Jiaotong University in China. After that, I came to the...
Mar 8, 2018 | Cancer Center News
ABSTRACT: Glioblastoma (GBM) is the most common, aggressive, and deadly form of adult brain cancer, and is associated with a short survival rate (median 12–15 months, 5+ year less than 5%). The complex tumor microenvironment includes matrix transitions at the tumor...
Nov 27, 2017 | Cancer Center News
Timothy Fan and Paul Hergenrother A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the...
